An official website of the United States government
Home
Name
Alemtuzumab
Alternate Names
Campath
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Targeted therapy
NSC Number
715969
Primary Site
Leukemia
lymphoma
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code alemtuzumab as BRM/Immunotherapy.For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved use on chronic lymphocytic leukemia.
FDA approved use on chronic lymphocytic leukemia.
Coding
This drug should be coded
